Figure 3

Antiproliferative effects of the (P)RR Ab on human glioblastoma cell lines in vitro and in vivo. The (P)RR Ab dose-dependently reduced cell proliferation in WST-1 (n = 3) and cell numbers (n = 4) in (A) U251MG cells and (B) U87MG cells (scale bar = 200 µm). (C) In vivo antitumor effect of systemic administration of the (P)RR Ab on engrafted tumors of U87MG cells in athymic nude mice 20 days after injection (left), and time dependent changes in tumor volume (right). The mean tumor volume after 20 days was 1730 ± 399 mL vs. 2739 ± 707 mL (P < 0.01, n = 7). *P < 0.05; **P < 0.01; ***P < 0.001.